Overview A Study to Evaluate the Efficacy and Safety of AD-209 Status: Not yet recruiting Trial end date: 2024-02-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy and safety of AD-209 Phase: Phase 2 Details Lead Sponsor: Addpharma Inc.